Literature DB >> 27020640

An unusual case of prolonged post-endoscopic retrograde cholangiopancreatography jaundice.

Georgios Tziatzios1, Paraskevas Gkolfakis, Ioannis S Papanikolaou, George Dimitriadis, Konstantinos Triantafyllou.   

Abstract

Despite the effectiveness of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of choledocholithiasis, various complications have been described. We herein report the first case of prolonged post-ERCP jaundice due to toxicity of the contrast agent Iobitridol (®XENETIX, Guerbet, Roissy CdG Cedex, France) in a patient who underwent ERCP with sphincterectomy and common bile duct stone removal. While clinical improvement and normalization of aminotransferases and cholestatic enzymes after the procedure, an unexplained increase of direct bilirubin was noticed. A second ERCP was performed one week later, excluding possible remaining choledocholithiasis. Nevertheless, serum direct bilirubin increased further up to 15 mg/dL. Other potential causes of direct hyperbilirubinemia were ruled out and patient's liver biopsy was compatible with drug-induced liver toxicity. Additionally, the cause-result time connection between the use of Iobitridol and bilirubin increase indicated the possibility of a toxic effect related to the repeated use of the particular contrast agent. Iobitridol, a contrast agent, can induce prolonged direct hyperbilirubinemia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27020640     DOI: 10.1016/s1499-3872(15)60402-7

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  2 in total

Review 1.  Prolonged cholestasis following endoscopic retrograde cholangiopancreatography, a rare complication of contrast agent induced liver injury: A case report and literature review.

Authors:  Cheng-Kuan Lin; Wen-Chih Huang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

2.  Gilbert syndrome combined with prolonged jaundice caused by contrast agent: Case report.

Authors:  Jian-Dan Qian; Feng-Qin Hou; Tai-Ling Wang; Chen Shao; Gui-Qiang Wang
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.